LATEST ARTICLES
SEARCH INDEX
SUGGEST ARTICLE
THE OSI COLLECTIONS
ABOUT THE OSI

OSI STATISTICS

Total abstracts indexed:
349
Open access articles:
289
Pending review:
69
Annotations added:
2
Countries represented:
81
No. of contributors:
10
Bookmarks made:
9
Specialities covered:
17

Retrospective Analysis of Chilean and Mexican GI Stromal Tumor Registries: A Tale of Two Latin American Realities


JournalJCO Global Oncology
Publication date – Apr – 2020
Authors – Germán Calderillo , Matías Muñoz-Medel , Edelmira Carbajal , Miguel Córdova-Delgado , Doris Durán , Ignacio N Retamal , Piga Fernández , Absalón Espinoza , Rodrigo Salas , María de la Paz Mastretta , Héctor Galindo , Bruno Nervi , Jorge Madrid , Cesar Sánchez , Carolina Ibáñez , José Peña , Sebastián Mondaca , Francisco Acevedo , Erica Koch , Mauricio P Pinto , Marcelo Garrido
Keywordsand outcomes, clinical characteristics, GI stromal tumors (GIST), postsurgery risk of recurrence, prevalence
Open access – Yes
SpecialitySurgical oncology
World region South America
Country: Chile, Mexico
Language – English
Submitted to the One Surgery Index on May 10, 2020 at 8:04 am
Abstract:

Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America.

Patients and methods: Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients’ clinical characteristics, including survival rates, through retrospective analysis.

Results: Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries.

Conclusion: To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias.

OSI Number – 20333
PMID – 32324433


Public annotations on this article:
No public annotations yet